tirzepatide dosage microdose Micro-Dose Program | Weight Maintenance Microdosing Tirzepatide Chart: A Monthly

Safety is a critical factor to consider when evaluating long-term cardiometabolic therapies

Semaglutide GLP-1 has shown promising results in weight loss among non-diabetic individuals, indicating its effectiveness extends beyond its initial purpose for managing diabetes

Neuroprotective effects, with a decreased risk of Alzheimers disease, dementia, and seizures

Glutathione delivered directly into the bloodstream via IV drips bypasses the digestive system, leading to immediate absorption and utilisation by the body

Key Development : In Dec 2025, Novo Nordisk announced that the FDA approved the Wegovy pill (once-daily oral semaglutide 25 mg) to reduce excess body weight and maintain weight reduction long term, and to reduce the risk of major adverse cardiovascular events the first oral GLP-1 receptor agonist therapy approved for weight management